Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
50%
Ph phase_4
1
25%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(2)
Other(1)

Detailed Status

Withdrawn2
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

withdrawn250%
unknown125%
completed125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)

NCT04966702
withdrawnphase_2

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

NCT03553615
withdrawnphase_3

Outpatient Use of Ivermectin in COVID-19

NCT04530474
unknownphase_4

Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection

NCT04435587

Clinical Trials (4)

Showing 4 of 4 trials
NCT04966702Phase 3

Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)

Completed
NCT03553615Phase 2

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

Withdrawn
NCT04530474Phase 3

Outpatient Use of Ivermectin in COVID-19

Withdrawn
NCT04435587Phase 4

Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4